New stock news | Cancer early screening track welcomes heavyweight player Amyson submits application to Hong Kong Stock Exchange Core products have been approved by the National Medical Products Administration.

According to the disclosure of the Hong Kong Stock Exchange on April 7th, Wuhan Emerson Life Sciences Co., Ltd. (referred to as Emerson) has submitted a listing application to the main board of the Hong Kong Stock Exchange, with Joint Sponsors being CICC International and BOCOM INTL. Emerson focuses on the development of early detection products for high incidence, high mortality rate cancers, and has successfully created a product pipeline covering multiple high-incidence cancers such as liver cancer, urinary tract epithelial cancer, colorectal cancer, and esophageal cancer. According to its prospectus, as of April 1, 2026, the company has had five products approved by the National Medical Products Administration as Class III medical devices, ranking first in the field of early cancer detection in China in terms of the number of certifications obtained. According to Frost & Sullivan data, in 2024, the incidence rate of liver cancer in China ranked fourth, the cancer-related mortality rate ranked second, and urinary tract epithelial cancer has a high recurrence characteristic. Early detection of these cancers can significantly improve survival rates while lowering medical costs associated with late-stage treatment. Tumor molecular testing in China is still in its early stages, but according to Frost & Sullivan data, this field is rapidly developing, with market value increasing from 43 billion RMB in 2019 to 87 billion RMB in 2024, with a compound annual growth rate of 15.2%. The market is expected to reach 38.8 billion RMB by 2033, with a compound annual growth rate of 18.1% from 2024 to 2033. Emerson's core competitiveness lies in its two globally pioneering core products. Emersonian, as the world's first early detection product for methylation-mediated liver cancer based on qPCR technology, was approved by NMPA in January 2025. The test uses internally developed specialized cfDNA extraction and conversion kits to process plasma samples, sensitively detecting trace amounts of ctDNA in cfDNA. Its clinical data shows a sensitivity of 92.33% and specificity of 93.35% for liver cancer detection, with a particularly high sensitivity of 84.43% for stage I liver cancer, significantly superior to traditional alpha-fetoprotein testing. As a non-invasive urine detection product, Emersonian uses new methylated biomarkers AL021918.2 gene and VIM gene, with high sensitivity and specificity. In October 2025, Emersonian obtained registration with the National Medical Products Administration as a Class III medical device. Additionally, Emersonian has good sample efficiency and convenience. It only requires 1 ml of urine sample for testing, much lower than the 50 ml typically required by comparable products. The test demonstrated excellent performance with a sensitivity of 92.94% and a specificity of 92.83% in clinical validation with 1571 samples, showing over 90.00% sensitivity across various subtypes of urinary tract epithelial cancer. Emerson uses cost-effective qPCR technology supported by the company's proprietary Intelligent Tumor Biomarker Finder (iTBFinder) platform developed based on cancer patient data, along with technologies such as Amplification Selective Capture (AS-Cap) and Sensitivity-Enhanced Methylation PCR (SEM-PCR) to significantly enhance detection capabilities. According to the prospectus, with the outstanding performance of products such as Aichangkang, Aichangjian, and Aisin in the market, Emerson's commercialization pace has significantly accelerated. The company's revenue increased by 113.0% from 7.238 million RMB in 2024 to 15.419 million RMB in 2025. The gross profit margin also increased from 56.9% to 78.1%.